Table 2. The types of surgery and treatment response after neoadjuvant therapy.
| Variable | Total population (n=1,312), n (%) |
|---|---|
| Surgery | |
| Mastectomy | 1,287 (98.1) |
| Modified radical mastectomy | 1,245 (96.7) |
| Radical mastectomy | 24 (1.9) |
| Skin-sparing mastectomy | 18 (1.4) |
| Breast conserving surgery | 25 (1.9) |
| Treatment response | |
| Response of primary tumor† | |
| pCR | 153 (11.7) |
| No pCR | 1,145 (87.2) |
| cCR | 103 (9.0) |
| PR | 618 (54.0) |
| SD | 395 (34.5) |
| PD | 29 (2.5) |
| Unknown | 14 (1.1) |
| Response of axillary lymph nodes | |
| ypN‡ | |
| ypN0 | 491 (37.4) |
| ypN1 | 363 (27.7) |
| ypN2 | 245 (18.7) |
| ypN3 | 169 (12.9) |
| Unknown | 44 (3.3) |
| Axilla response§ | |
| pCR | 491 (37.4) |
| No pCR | 777 (59.3) |
| Unknown | 44 (3.3) |
Data are shown in number of patients (%). pCR, pathologic complete response; cCR, clinical complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCIS, ductal carcinoma in situ. †, a pCR of the primary tumor for breast cancer referred to no evidence of residual invasive carcinoma (DCIS allowed) in the excisional breast specimen according to Miller & Payne classification (21). However, the objective response rate of primary tumor was evaluated on the basis of RECIST 1.1 (the Response Evaluation Criteria in Solid Tumors, version 1.1) principle, as classified as cCR, PR, SD and PD (22); ‡, the pathologic classification of axillary lymph nodes after neoadjuvant therapy was documented according to the 8th edition of AJCC (American Joint Committee on Cancer) Cancer Staging Manual (20); §, a pCR of the axillary lymph nodes was defined as absence of measurable or metastatic disease in the excisional specimen of axillary lymph nodes, otherwise regarded as no pCR.